Ryne Biotechnology Inc. has announced a $4 million Clinical Stage Research Program grant from the California Institute for Regenerative Medicine to advance its lead candidate for the treatment of Parkinson’s disease.

According to a company press release, RNDP-001 is a dopamine neuron progenitor derived from induced pluripotent stem cells for treatment of both inherited and idiopathic forms of PD.

The novel therapeutic has completed preclinical efficacy and safety studies, the company stated, and the research grant will allow Ryne Bio to submit an investigational new drug application to the FDA within the next 12 months. [1]

Figure 1. Grant awarded to Ryne Biotechnology to develop Parkinson's treatment

Grant awarded to Ryne Biotechnology to develop Parkinson's treatment is shown in figure 1. RYNE Bio is a biotechnology company developing therapies for neurodegenerative movement disorders, such as Parkinson's disease.

It provides neuron replacement therapies that are available off-the-shelf as an effective disease-modifying therapy for neurological illnesses, giving clinicians access to newer methods for treating conditions like Parkinson's. The company was founded in 2022 and is based in Cambridge, Massachusetts.[2]

San Diego-based Ryne Biotechnology, a company developing stem cell technology to treat neurological disorders, says it has received a $4M grant from the California Institute for Regenerative Medicine (CIRM).

The company said it will use the funding advance its lead candidate RNDP-001, an iPSC-derived dopamine neuron progenitor for the treatment of both inherited and idiopathic forms of Parkinson’s disease, through submission of an Investigational New Drug (IND) application. Nick Manusos is CEO of Ryne Bio. [3]

That's great news! Ryne Biotechnology receiving a grant to advance Parkinson's therapy is a positive development in the field of medical research. Parkinson's disease is a neurodegenerative disorder that affects millions of people worldwide, and advancements in therapy can significantly improve the quality of life for those affected.

With the grant, Ryne Biotechnology will have the resources to further their research and development efforts in Parkinson's therapy. They may explore various avenues such as developing new drugs, refining existing treatments, or investigating novel approaches to managing the symptoms and progression of the disease.

It's worth noting that Parkinson's disease is a complex condition, and developing effective therapies requires extensive research and testing. However, every step forward in this area brings us closer to better treatments and improved outcomes for individuals living with Parkinson's.

Overall, the grant received by Ryne Biotechnology represents an encouraging step forward in the pursuit of improved Parkinson's therapy, and it highlights the commitment of researchers and organizations in addressing this challenging disease.

References:

1. https://www.healio.com/news/neurology/20230216/ryne-biotechnology-awarded-4m-to-advance-therapies-for-parkinsons-other-cns-disorders
2. https://www.cbinsights.com/company/ryne-bio
3. https://www.socaltech.com/ryne_biotechnology_snags_4m_grant/s-0083219.html

Cite this article:

Gokula Nandhini K (2023), Grant awarded to Ryne Biotechnology to develop Parkinson's treatment, Anatechmaz,pp 199